Interim analysis of data from the phase III PACIFIC trial of durvalumab to treat non-small-cell lung cancer (NSCLC) in patients who had not progressed following chemo-radiotherapy indicates that the trial has already the primary endpoint of extending progression-free survival.

Other endpoints include overall survival, with data forthcoming as the trial progresses.

Durvalumab has recently received accelerated FDA approval for treating relapsed bladder cancer, and was found to be complimentary to tremelimumab in a phase Ib trial last year.

Further phase III MYSTIC and PEARL trials are assessing durvulamab as first-line monotherapy for NSCLC, and further tests of its action alongside tremelimumab are being conducted in the POSEIDON and NEPTUNE phase III trials. 

"These are highly encouraging results for patients with locally-advanced lung cancer for whom surgery is not an option," said Sean Bohen, Astra's chief medical officer. "We look forward to working with regulatory authorities around the world to bring durvalumab to lung cancer patients as soon as possible. Alongside this, we continue to explore [it's] full potential as monotherapy as well as in combination with tremelimumab and other medicines in areas of continued unmet need across multiple types of cancer."

Source: AstraZeneca